TARS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TARS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Tarsus Pharmaceuticals's EPS without NRI for the three months ended in Dec. 2023 was $-1.33.
During the past 3 years, the average EPS without NRI Growth Rate was -2.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was -42.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 6 years, the highest 3-Year average EPS without NRI Growth Rate of Tarsus Pharmaceuticals was -2.40% per year. The lowest was -25.90% per year. And the median was -9.80% per year.
For the Biotechnology subindustry, Tarsus Pharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Tarsus Pharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Tarsus Pharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
Tarsus Pharmaceuticals (NAS:TARS) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Thank you for viewing the detailed overview of Tarsus Pharmaceuticals's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Bobak R. Azamian | director, 10 percent owner, officer: President and CEO | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Jose M. Trevejo | officer: Chief Medical Officer | C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Andrew D. Goldberg | director | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Dianne C. Whitfield | officer: Chief Human Resources Officer | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Bryan Wahl | officer: General Counsel | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Elizabeth Yeu Lin | director | 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630 |
Aziz Mottiwala | officer: Chief Commercial Officer | 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401 |
Jeffrey S Farrow | officer: See Remarks | TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080 |
Leonard M. Greenstein | officer: Chief Financial Officer | 24562 BELGREEN PLACE, LAKE FOREST CA 92630 |
Seshadri Neervannan | officer: Chief Operating Officer | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Mark J. Holdbrook | officer: V.P., Clinical Affairs | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Scott W Morrison | director | C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080 |
Vivo Capital Fund Ix, L.p. | 10 percent owner | 192 LYTTON AVENUE, PALO ALTO CA 94301 |
Michael Ackermann | director, 10 percent owner | 202 CARNEGIE CENTER, SUITE 109, PRINCETON NJ 08540 |
Rosemary A Crane | director | C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873 |
From GuruFocus
By GlobeNewswire • 08-02-2023
By Value_Insider Value_Insider • 12-16-2022
By sperokesalga sperokesalga • 06-05-2023
By GuruFocus Research GuruFocus Editor • 05-20-2023
By PurpleRose PurpleRose • 08-05-2022
By Marketwired • 08-24-2023
By sperokesalga sperokesalga • 03-02-2023
By GuruFocus Research GuruFocus Editor • 01-15-2023
By GuruFocus Research GuruFocus Editor • 05-21-2023
By sperokesalga sperokesalga • 05-03-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.